Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants

The use of monoclonal neutralizing antibodies (mNAbs) is being actively pursued as a viable intervention for the treatment of Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) infection and associated coronavirus disease 2019 (COVID-19). While highly potent mNAbs have great therapeutic potential,...

Descripción completa

Detalles Bibliográficos
Autores principales: Oladunni, Fatai S., Park, Jun-Gyu, Chiem, Kevin, Ye, Chengjin, Pipenbrink, Michael, Walter, Mark R., Kobie, James, Martinez-Sobrido, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837211/
https://www.ncbi.nlm.nih.gov/pubmed/33513380
http://dx.doi.org/10.1016/j.jviromet.2021.114084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837211/
https://www.ncbi.nlm.nih.gov/pubmed/33513380
http://dx.doi.org/10.1016/j.jviromet.2021.114084

Ejemplares similares